Physician profile
Stuart K Brown
NPI 1326033531
$5,065.61
in general payments reported to CMS, 2019-2025
19 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $375 · 2021: $678 · 2022: $963 · 2023: $939 · 2024: $803 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,525.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $747.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $451.40 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.40 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $274.21 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Mylan Specialty L.P. | $200.15 | 2019-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $83.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $67.41 | 2019-2021 | |
| Abbvie INC. | $49.36 | 2024 | |
| Dexcom, INC. | $38.13 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $37.77 | 2022-2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $26.73 | 2019 | |
| Exact Sciences Corporation | $22.42 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $21.08 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.32 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $16.49 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.50 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.